Phathom Pharmaceuticals (PHAT) investor relations material

Strategic focus and operational changes

• Leadership prioritized financial discipline and efficiency, pivoting commercial efforts toward gastroenterology, which proved to be the most productive segment for growth.

• Sales calls shifted from primary care to gastroenterology, resulting in a 4x efficiency gain and driving the majority of prescription growth.

• Direct-to-consumer (DTC) spending was significantly reduced as it was deemed premature, reallocating resources to higher ROI activities.

• Operating expenses were cut by 50% from the first to the second half of the year, supporting profitability goals.

• The company now maintains a lean expense base, with future investments tied to clear, positive ROI opportunities.

Financial structure and guidance

• A $130 million equity raise and debt restructuring extended term debt maturity to 2029, enhancing financial flexibility and sustainability.

• The company provided its first full-year outlook, projecting $140 million incremental revenue at the midpoint, driven by increased sales force focus on gastroenterology.

• Guidance is based on achievable internal plans, with transparency in reporting and a recent reclassification of certain costs to cost of goods sold, which has no economic impact.

• Revenue is expected to be weighted 40% in the first half and 60% in the second half of the year, reflecting typical industry seasonality.

• Expense run rate is expected to remain stable, with slight increases for field force expansion, clinical trials, and marketing pilots.

Market opportunity and growth trajectory

• The product targets the 30%-40% of PPI patients still experiencing pain, representing a multi-billion dollar opportunity.

• Achieving a 20%-25% conversion rate among gastroenterology prescriptions could yield $1 billion in annual revenue; current top prescribers are already at this level.

• A second $1 billion opportunity exists as patients cycle back to primary care, where future adoption is expected to grow as awareness increases.

• The product’s persistence and efficacy support long-term patient retention and recurring revenue.

• Expansion into non-erosive indications and broader primary care adoption are anticipated to drive further growth in coming years.